RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Robert Kirken to Protein-Tyrosine Kinases

This is a "connection" page, showing publications Robert Kirken has written about Protein-Tyrosine Kinases.
Connection Strength

3.401
  1. Grant AH, Ayala-Marin YM, Mohl JE, Robles-Escajeda E, Rodriguez G, Dutil J, Kirken RA. The Genomic Landscape of a Restricted ALL Cohort from Patients Residing on the U.S./Mexico Border. Int J Environ Res Public Health. 2021 07 09; 18(14).
    View in: PubMed
    Score: 0.733
  2. Stepkowski SM, Kirken RA. Janus tyrosine kinases and signal transducers and activators of transcription regulate critical functions of T cells in allograft rejection and transplantation tolerance. Transplantation. 2006 Aug 15; 82(3):295-303.
    View in: PubMed
    Score: 0.261
  3. Nagy ZS, Ross J, Cheng H, Stepkowski SM, Kirken RA. Regulation of lymphoid cell apoptosis by Jaks and Stats. Crit Rev Immunol. 2004; 24(2):87-110.
    View in: PubMed
    Score: 0.218
  4. Stepkowski SM, Erwin-Cohen RA, Behbod F, Wang ME, Qu X, Tejpal N, Nagy ZS, Kahan BD, Kirken RA. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood. 2002 Jan 15; 99(2):680-9.
    View in: PubMed
    Score: 0.190
  5. Kirken RA. Targeting Jak3 for immune suppression and allograft acceptance. Transplant Proc. 2001 Nov-Dec; 33(7-8):3268-70.
    View in: PubMed
    Score: 0.187
  6. Stepkowski SM, Nagy ZS, Wang ME, Behbod F, Erwin-Cohen R, Kahan BD, Kirken RA. PNU156804 inhibits Jak3 tyrosine kinase and rat heart allograft rejection. Transplant Proc. 2001 Nov-Dec; 33(7-8):3272-3.
    View in: PubMed
    Score: 0.187
  7. Behbod F, Erwin-Cohen RA, Wang ME, Trawick BW, Qu X, Verani R, Kahan BD, Stepkowski SM, Kirken RA. Concomitant inhibition of Janus kinase 3 and calcineurin-dependent signaling pathways synergistically prolongs the survival of rat heart allografts. J Immunol. 2001 Mar 15; 166(6):3724-32.
    View in: PubMed
    Score: 0.179
  8. Kirken RA, Erwin-Cohen R, Behbod F, Wang M, Stepkowski SM, Kahan BD. Tyrphostin AG490 selectively inhibits activation of the JAK3/STAT5/MAPK pathway and rejection of rat heart allografts. Transplant Proc. 2001 Feb-Mar; 33(1-2):95.
    View in: PubMed
    Score: 0.178
  9. Kirken RA, Erwin RA, Wang L, Wang Y, Rui H, Farrar WL. Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells. J Immunol. 2000 Nov 01; 165(9):5097-104.
    View in: PubMed
    Score: 0.175
  10. Kirken RA, Erwin RA, Taub D, Murphy WJ, Behbod F, Wang L, Pericle F, Farrar WL. Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells. J Leukoc Biol. 1999 Jun; 65(6):891-9.
    View in: PubMed
    Score: 0.158
  11. Malabarba MG, Rui H, Deutsch HH, Chung J, Kalthoff FS, Farrar WL, Kirken RA. Interleukin-13 is a potent activator of JAK3 and STAT6 in cells expressing interleukin-2 receptor-gamma and interleukin-4 receptor-alpha. Biochem J. 1996 Nov 01; 319 ( Pt 3):865-72.
    View in: PubMed
    Score: 0.132
  12. Kirken RA, Rui H, Malabarba MG, Howard OM, Kawamura M, O'Shea JJ, Farrar WL. Activation of JAK3, but not JAK1, is critical for IL-2-induced proliferation and STAT5 recruitment by a COOH-terminal region of the IL-2 receptor beta-chain. Cytokine. 1995 Oct; 7(7):689-700.
    View in: PubMed
    Score: 0.123
  13. Kirken RA, Rui H, Malabarba MG, Farrar WL. Identification of interleukin-2 receptor-associated tyrosine kinase p116 as novel leukocyte-specific Janus kinase. J Biol Chem. 1994 Jul 22; 269(29):19136-41.
    View in: PubMed
    Score: 0.113
  14. Qiu L, Lai R, Lin Q, Lau E, Thomazy DM, Calame D, Ford RJ, Kwak LW, Kirken RA, Amin HM. Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood. 2006 Oct 01; 108(7):2407-15.
    View in: PubMed
    Score: 0.064
  15. Stepkowski SM, Kao J, Wang ME, Tejpal N, Podder H, Furian L, Dimmock J, Jha A, Das U, Kahan BD, Kirken RA. The Mannich base NC1153 promotes long-term allograft survival and spares the recipient from multiple toxicities. J Immunol. 2005 Oct 01; 175(7):4236-46.
    View in: PubMed
    Score: 0.061
  16. Wang M, Kirken R, Behbod F, Erwin-Cohen R, Stepkowski SM, Kahan BD. Inhibition of Jak3 tyrosine kinase by PNU156804 blocks rat heart allograft rejection. Transplant Proc. 2001 Feb-Mar; 33(1-2):201.
    View in: PubMed
    Score: 0.044
  17. Yen CH, Yang YC, Ruscetti SK, Kirken RA, Dai RM, Li CC. Involvement of the ubiquitin-proteasome pathway in the degradation of nontyrosine kinase-type cytokine receptors of IL-9, IL-2, and erythropoietin. J Immunol. 2000 Dec 01; 165(11):6372-80.
    View in: PubMed
    Score: 0.044
  18. Stepkowski SM, Kirken RA. The role of IL-2 in allograft rejection--a lesson learned from experimental work. Transplantation. 2000 Jun 27; 69(12):2480-2.
    View in: PubMed
    Score: 0.043
  19. Wang LH, Kirken RA, Yang XY, Erwin RA, DaSilva L, Yu CR, Farrar WL. Selective disruption of interleukin 4 autocrine-regulated loop by a tyrosine kinase inhibitor restricts activity of T-helper 2 cells. Blood. 2000 Jun 15; 95(12):3816-22.
    View in: PubMed
    Score: 0.043
  20. Wang LH, Kirken RA, Erwin RA, Yu CR, Farrar WL. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response. J Immunol. 1999 Apr 01; 162(7):3897-904.
    View in: PubMed
    Score: 0.039
  21. Kirken RA, Evans GA, Duh? RJ, DaSilva L, Malabarba MG, Erwin RA, Farrar WL. Mechanisms of cytokine signal transduction: IL-2, IL-4 and prolactin as hematopoietin receptor models. Vet Immunol Immunopathol. 1998 May 15; 63(1-2):27-36.
    View in: PubMed
    Score: 0.037
  22. Duh? RJ, Evans GA, Erwin RA, Kirken RA, Cox GW, Farrar WL. Nitric oxide and thiol redox regulation of Janus kinase activity. Proc Natl Acad Sci U S A. 1998 Jan 06; 95(1):126-31.
    View in: PubMed
    Score: 0.036
  23. Malabarba MG, Kirken RA, Rui H, Koettnitz K, Kawamura M, O'Shea JJ, Kalthoff FS, Farrar WL. Activation of JAK3, but not JAK1, is critical to interleukin-4 (IL4) stimulated proliferation and requires a membrane-proximal region of IL4 receptor alpha. J Biol Chem. 1995 Apr 21; 270(16):9630-7.
    View in: PubMed
    Score: 0.030
  24. Rui H, Lebrun JJ, Kirken RA, Kelly PA, Farrar WL. JAK2 activation and cell proliferation induced by antibody-mediated prolactin receptor dimerization. Endocrinology. 1994 Oct; 135(4):1299-306.
    View in: PubMed
    Score: 0.029
  25. DaSilva L, Howard OM, Rui H, Kirken RA, Farrar WL. Growth signaling and JAK2 association mediated by membrane-proximal cytoplasmic regions of prolactin receptors. J Biol Chem. 1994 Jul 15; 269(28):18267-70.
    View in: PubMed
    Score: 0.028
  26. Johnston JA, Kawamura M, Kirken RA, Chen YQ, Blake TB, Shibuya K, Ortaldo JR, McVicar DW, O'Shea JJ. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature. 1994 Jul 14; 370(6485):151-3.
    View in: PubMed
    Score: 0.028
  27. Rui H, Kirken RA, Farrar WL. Activation of receptor-associated tyrosine kinase JAK2 by prolactin. J Biol Chem. 1994 Feb 18; 269(7):5364-8.
    View in: PubMed
    Score: 0.027
  28. Stepkowski SM, Kirken RA, Nagy ZS, Trawick BW, Wang M, Tejpal N, Wang ME, Tian L, Clark J, Kahan BD. The role of Stat5 in the induction of regulatory T cells in transplantation tolerance. Transplant Proc. 2001 Nov-Dec; 33(7-8):3835-6.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support